Niagen Bioscience, Inc. (NASDAQ:NAGE) Stock Has Average Target Price of $10.33 According to Brokerages

Niagen Bioscience, Inc. (NASDAQ:NAGE) has been assigned an average recommendation of “Buy” from the five ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $10.33.

NAGE has been the subject of several research analyst reports. Roth Capital restated a “buy” rating on shares of Niagen Bioscience in a report on Wednesday, August 5th. Freedom Capital raised Niagen Bioscience to a “strong-buy” rating in a research report on Monday, July 6th. Weiss Ratings restated a “hold (c)” rating on shares of Niagen Bioscience in a research report on Friday, July 17th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Niagen Bioscience in a research note on Wednesday, July 1st.

Institutional Trading of Niagen Bioscience

A number of hedge funds have recently modified their holdings of the business. Tidal Investments LLC bought a new position in shares of Niagen Bioscience in the 2nd quarter worth about $394,000. Squarepoint Ops LLC boosted its stake in Niagen Bioscience by 33.3% during the second quarter. Squarepoint Ops LLC now owns 123,054 shares of the company’s stock worth $393,000 after acquiring an additional 30,711 shares in the last quarter. Tieton Capital Management LLC bought a new stake in Niagen Bioscience during the second quarter worth about $6,407,000. Bank of New York Mellon Corp purchased a new stake in Niagen Bioscience in the second quarter worth about $647,000. Finally, Stoneridge Investment Partners LLC purchased a new stake in Niagen Bioscience in the second quarter worth about $49,000. Institutional investors own 15.41% of the company’s stock.

Niagen Bioscience Price Performance

NASDAQ NAGE opened at $2.92 on Thursday. The stock has a market capitalization of $232.55 million, a PE ratio of 16.22 and a beta of 2.09. Niagen Bioscience has a 1 year low of $2.87 and a 1 year high of $9.28. The business’s 50-day moving average is $3.13 and its 200 day moving average is $3.69.

Niagen Bioscience (NASDAQ:NAGE) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $0.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.01. Niagen Bioscience had a net margin of 12.39% and a return on equity of 17.95%. The business had revenue of $29.78 million for the quarter, compared to the consensus estimate of $29.95 million. As a group, equities research analysts anticipate that Niagen Bioscience will post 0.13 earnings per share for the current year.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a bioscience company focused on developing and commercializing products designed to support healthy aging and cellular energy metabolism. The company’s research centers on nicotinamide riboside (NR), a form of vitamin B3 and precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme involved in numerous cellular processes.

The company markets its proprietary NIAGEN branded NR ingredient to supplement manufacturers and sells consumer products under the Tru Niagen brand.